Efficacy of a novel large-cell Niti-S stent with a slim delivery system for hilar biliary obstruction: a preliminary study.


Journal

Annals of medicine
ISSN: 1365-2060
Titre abrégé: Ann Med
Pays: England
ID NLM: 8906388

Informations de publication

Date de publication:
12 2022
Historique:
entrez: 12 4 2022
pubmed: 13 4 2022
medline: 15 4 2022
Statut: ppublish

Résumé

The large-cell Niti-S stent is useful for multiple stenting in patients with malignant hilar biliary obstruction (MHBO). Recently, a novel uncovered self-expandable metallic stent (USEMS) (a Niti-S large-cell SR slim delivery system) was developed. In this study, we aimed to evaluate the efficacy of this USEMS slim delivery system in MHBO patients. Outcomes related to USEMS placement, the clinical course, and the period to recurrent biliary obstruction (RBO) were evaluated in MHBO patients who received multiple USEMSs with the Niti-S large-cell SR slim delivery system. Twenty-two MHBO patients underwent the placement of multiple USEMSs, including the novel slim-delivery stent. Six patients had a past history of upper gastrointestinal reconstruction (Billroth I: 1, Billroth II: 4, Roux-en-Y: 1). The number of USEMSs placed in each patient was 2-6. Three procedures were reinterventions. The new slim delivery system was placed as the first stent in ten patients and as an additional stent in the remaining patients. Seven patients were drained using only Niti-S large-cell SR slim delivery stents. The technical and clinical success rates were both 100%. Placing multiple USEMSs in patients with a past history of abdominal surgery or in reintervention is difficult. Although difficult cases were included in this study, stent-in-stent placement with the novel Niti-S large-cell SR slim delivery system was useful in treating MHBO patients. In addition, this novel stent might be the first choice for MHBO patients.KEY MESSAGESEndoscopic multistenting for MHBO is challenging. In addition, reintervention or multistenting for MHBO patients with a past history of abdominal surgery becomes more difficult.The novel Niti-S large-cell SR slim delivery USEMS is useful as an additional stent because the delivery system is thin and suitable for a 0.025 guidewire. In addition, the novel stent is of the braided type and has a large mesh. Therefore, the novel stent is expected to have strong radial force and can be used as the first SEMS.The Niti-S large-cell SR slim delivery stent is long enough to be used in patients with upper gastrointestinal reconstruction. Although this study included patients with reintervention or a past history of upper gastrointestinal reconstruction, the technical success rate of multiple stenting for MHBO patients was 100%. The slim-delivery stent might overcome several difficulties of endoscopic multistenting.

Identifiants

pubmed: 35412414
doi: 10.1080/07853890.2022.2056631
pmc: PMC9009962
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

953-961

Références

Gastrointest Endosc. 2010 Sep;72(3):632-6
pubmed: 20579991
J Hepatobiliary Pancreat Sci. 2013 Feb;20(2):214-22
pubmed: 22415652
Dig Endosc. 2021 Jan;33(1):179-189
pubmed: 32249460
Dig Endosc. 2014 Jan;26(1):93-9
pubmed: 23517109
Endosc Int Open. 2019 Oct;7(10):E1288-E1292
pubmed: 31579711
Gastrointest Endosc. 2017 Nov;86(5):817-827
pubmed: 28479493
Endoscopy. 2022 Jun;54(6):E302-E303
pubmed: 34215008
Dig Endosc. 2016 Nov;28(7):731-737
pubmed: 27088888
Endoscopy. 2022 May;54(5):E224-E225
pubmed: 34058758
Dig Endosc. 2015 Sep;27(6):692-9
pubmed: 25708157
Dig Endosc. 2015 Jan;27(2):259-64
pubmed: 25209944
Intern Med. 2021 Jun 15;60(12):1871-1876
pubmed: 33518571
Surg Endosc. 2011 Feb;25(2):463-7
pubmed: 20602139
Gastrointest Endosc. 1991 May-Jun;37(3):383-93
pubmed: 2070995
J Hepatobiliary Pancreat Sci. 2021 Oct 11;:
pubmed: 34633149
World J Gastroenterol. 2017 Sep 14;23(34):6273-6280
pubmed: 28974893
Gastrointest Endosc. 2013 Apr;77(4):593-600
pubmed: 23290720
J Hepatobiliary Pancreat Sci. 2015 Jan;22(1):79-85
pubmed: 25308061
Surg Laparosc Endosc Percutan Tech. 2019 Feb;29(1):43-48
pubmed: 30418421

Auteurs

Mitsuru Sugimoto (M)

Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Department of Gastroenterology, Saiseikai Fukushima General Hospital, Fukushima, Japan.

Tadayuki Takagi (T)

Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan.

Rei Suzuki (R)

Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan.

Naoki Konno (N)

Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Department of Gastroenterology, Fukushima Red Cross Hospital, Fukushima, Japan.

Hiroyuki Asama (H)

Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Department of Gastroenterology, Fukushima Red Cross Hospital, Fukushima, Japan.

Yuki Sato (Y)

Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan.

Hiroki Irie (H)

Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan.

Yuto Ishizaki (Y)

Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Department of Gastroenterology, Saiseikai Fukushima General Hospital, Fukushima, Japan.

Hidenobu Akatsuka (H)

Department of Gastroenterology, Saiseikai Fukushima General Hospital, Fukushima, Japan.

Jun Nakamura (J)

Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Department of Endoscopy, Fukushima Medical University Hospital, Fukushima, Japan.

Mika Takasumi (M)

Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan.

Minami Hashimoto (M)

Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Department of Endoscopy, Fukushima Medical University Hospital, Fukushima, Japan.

Tsunetaka Kato (T)

Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Department of Endoscopy, Fukushima Medical University Hospital, Fukushima, Japan.

Ryoichiro Kobashi (R)

Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Department of Endoscopy, Fukushima Medical University Hospital, Fukushima, Japan.

Takumi Yanagita (T)

Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan.

Shigeru Marubashi (S)

Department of Hepato-Biliary-Pancreatic and Transplant Surgery, School of Medicine, Fukushima Medical University, Fukushima, Japan.

Takuto Hikichi (T)

Department of Endoscopy, Fukushima Medical University Hospital, Fukushima, Japan.

Hiromasa Ohira (H)

Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH